Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Inflammatory or Locally Advanced Breast Cancer
NCT00016549Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2001
- Primary completion
- Jan 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in inflammatory breast cancer (IBC) and breast cancer, sponsored by National Cancer Institute. Primary endpoint: Change in angiogenesis parameters (molecular and dynamic MRI) at 3 weeks. Started May 2001; status: completed.
02
Drugs
bevacizumab
03
Conditions
inflammatory breast cancer (IBC)breast cancer
Beyond the preview
Go deeper on NCT00016549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00016549.